Company Description
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs.
The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD).
It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases.
In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions.
It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation.
The company was founded in 2005 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 102 |
| CEO | Linda Marbán |
Contact Details
Address: 10865 Road to the Cure, Suite 150 San Diego, California 92121 United States | |
| Phone | 858 727 1755 |
| Website | capricor.com |
Stock Details
| Ticker Symbol | CAPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001133869 |
| CUSIP Number | 14070B309 |
| ISIN Number | US14070B3096 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Linda Marbán Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Frank Isaac Litvack FACC, M.D. | Executive Chairman of the Board |
| Anthony J. Bergmann M.B.A. | Chief Financial Officer and Corporate Treasurer |
| Karen G. Krasney | Executive Vice President, General Counsel and Secretary |
| Dr. Kristi A. H. Elliott Ph.D. | Chief Science Officer |
| Catherine Lee Kelleher | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | EFFECT | Notice of Effectiveness |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 22, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 17, 2024 | 424B5 | Filing |
| Oct 17, 2024 | 8-K | Current Report |
| Oct 16, 2024 | EFFECT | Notice of Effectiveness |